drugset / Trial / NCT07110571
A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a multi-cohort, multi-center Phase II clinical study exploring the efficacy of treatment with either Adebrelimab plus SHR-A1811/SHR-A1904 and chemotherapy, or Adebrelimab plus SHR-8068 in patients with gastric or gastroesophageal junction (GEJ) cancer. The study also evaluates the safety and tolerability of these combination regimens.
Timeline
- Start
- 2025-08-28
- Primary completion
- 2026-08
- Completion
- 2027-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebrelimab | Monoclonal antibody | — | — |
| Subject | SHR-8068 | Monoclonal antibody | — | — |
| Subject | SHR-A1904 | Unknown | — | — |
| Subject | Trastuzumab Rezetecan | Monoclonal antibody | — | — |